glp 1 receptor agonists for type 2 diabetes GLP-1 in the treatment of – state-of-the-art GLP1-GIP receptor co-agonists: a promising

GLP-1 agonists were originally used to control diabetes

Kanoski et al., 2011

Compared with the NC group, animal experiments found that the serum aspartate transaminase (AST), alanine transaminase (ALT), total cholesterol (TC), and TG were increased in the HF group, and the level of liver TG was also increased

Members lose 29% more weight with Med+ At 12 months, Med+ members prescribed a GLP-1 medication who engaged regularly with the GLP-1 Success Program lost 29.1% more body weight , on average, than those who did not engage in behavioral support*

GLP-1R populations in the nucleus accumbens (ACBs), paraventricular nucleus (PVH), lateral hypothalamus (LHA), and ventral tegmental area (VTA) are involved in food choice, reward, and taste aversion [40]

Efficacy and safety of Glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis